RGD Reference Report - The anti-fibrotic effect of a serine protease inhibitor in the kidney. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

The anti-fibrotic effect of a serine protease inhibitor in the kidney.

Authors: Morinaga, J  Kakizoe, Y  Miyoshi, T  Onoue, T  Ueda, M  Mizumoto, T  Yamazoe, R  Uchimura, K  Hayata, M  Shiraishi, N  Adachi, M  Sakai, Y  Tomita, K  Kitamura, K 
Citation: Morinaga J, etal., Am J Physiol Renal Physiol. 2013 May 22.
RGD ID: 7244171
Pubmed: PMID:23698112   (View Abstract at PubMed)
DOI: DOI:10.1152/ajprenal.00586.2012   (Journal Full-text)

Interstitial fibrosis is a final common pathway for the progression of chronic kidney diseases. Activated fibroblasts have an extremely important role in the progression of renal fibrosis, and transforming growth factor (TGF)-beta1 is a major activator of fibroblasts. Since previous reports indicate that serine protease inhibitors have a potential to inhibit TGF-beta1 signaling in vitro, we hypothesized that a synthetic serine protease inhibitor, camostat mesilate (CM), could slow the progression of renal fibrosis. TGF-beta1 markedly increased the phosphorylation of TGF-beta type I receptor (TbetaIR), ERK 1/2 and smad2/3, and the levels of pro-fibrotic markers, such as alphaSMA, CTGF, and PAI-1, in renal fibroblast (NRK-49F cells), and they were all significantly reduced by CM. In protocol 1, eight-week-old male Sprague-Dawley rats were subjected to unilateral ureteral obstruction (UUO) and were concurrently treated with a slow-release pellet of CM or vehicle for 14 days. Protocol 2 was similar to protocol 1, except that CM was administered 7 days after UUO. CM substantially improved the renal fibrosis that was determined by sirius red staining, collagen expression, and hydroxyproline levels. The phosphorylation of ERK1/2 and smad2/3, and the levels of alphaSMA, CTGF, proMMP-2, and MMP-2 were substantially increased by UUO, and they were all significantly attenuated by CM. These anti-fibrotic effects of CM were also observed in protocol 2. Our current results suggest the possibility that CM might represent a new class of therapeutic drugs for the treatment of renal fibrosis through the suppression of the TGF-beta1 signaling.

RGD Manual Disease Annotations    Click to see Annotation Detail View

Objects Annotated

Genes (Rattus norvegicus)
Mapk1  (mitogen activated protein kinase 1)

Genes (Mus musculus)
Mapk1  (mitogen-activated protein kinase 1)

Genes (Homo sapiens)
MAPK1  (mitogen-activated protein kinase 1)


Additional Information